This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Scientists then annotate the cells with this information, a process that can take days or even weeks, depending on the number of cells being labeled, and requires labor-intensive literature and database searches. We wanted to build a tool like that for cellbiology. Overall, how can AI help advance cellbiology?
The aim is to establish condensate biology as a fundamental branch of cellbiology – “cellbiology 2.0” The underlying biology and processes upon which the company was founded have broad applicability across various human disease areas. Klein notes the importance of Dewpoint’s disease-agnostic approach.
About the authors Aleta Pupovac Publications Officer, Cartherics Aleta is a cell biologist and immunologist who is passionate about translational science. In 2019, she joined Cartherics focusing on the science underpinning induced pluripotential stem cell differentiation to natural killer cells, and how to manufacture them.
Nikki drives adoption of 3D cellular models of human disease by applying her expertise in cellbiology to drug discovery and high-throughput screening. Nikki’s life sciences experience spans leadership, commercial and research roles. About the author Nikki Carter Commercial Organoid Innovation Director, Molecular Devices.
By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cellbiology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. Along the way, TIDE is showing how careful, systematic science at scale can quickly home in on promising drug targets.
By Leah Eisenstadt March 25, 2024 Credit: Allison Colorado, Broad Communications Alex Navarro, Senior Program Coordinator for the Broad Biomedical Post-baccalaureate Scholars Program Alex Navarro didn’t always aspire to a career in science. in cellbiology. It was fun to spend so much time watching cells divide.
Read the Article Rare Roundup The Jackson Laboratory offers “Exploring Rare Disease Through Translational Research” MiniCourse Human health is incredibly complex; developing safe, effective treatments requires knowledge of molecular mechanisms, cellbiology, and drug administration.
I sharpened my focus in my early teen age years when I decided I wanted to harness my interest in human biology to make medicines for people. I studied Natural Sciences at the University of Cambridge, where I was exposed to a range of disciplines from chemistry to physiology, specialising in my last year in biochemistry.
By Corie Lok November 2, 2023 Credit: Maria Nemchuk, Broad Communications Mehrtash Babadi is director of computational methods in Broad's Data Sciences Platform The recent explosion of generative AI tools has prompted many discussions in virtually all fields about the benefits and risks of these technologies.
I always knew I wanted to study biology. My interest in science started in grade school, then continued through high school and finally into college. I was sure that Biology would be my major, but it required studying maths, and this was my first obstacle. Understanding the connection between STEM subjects is critical.
A recently published study 1 from a large team of cell biologists sheds new light on cellular organisation and variability. SR: This project started in the early days of the Allen Institute for CellScience, nearly seven years ago. Can you give a brief overview of your research methods?
The research scientist at the Max Planck Institute for Medical Research received the award in recognition of his ground-breaking work in establishing various approaches to protein labeling in living cells that have enabled far-reaching advances in chemical and cellbiology. Early Excellence in Science Awards 2020.
Closing remarks Solution based science, but not problem-based science becomes the basis of success of science. From 3D cell culture to organs-on-chips. Trends in CellBiology. Science Translational Medicine. References Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. 2019;11(517).
I was ‘pre-med’ and got really interested in the science and especially the integration of chemistry and art. I struggled with going to graduate school in art conservation science, ie, the science of art, or more general chemistry, and I decided to do chemistry because it had broader opportunities. Integration is really the key.
." — Timothy Bates, University of Edinburgh I used to see peer review as primarily good — an important gatekeeping process, essential for protecting capital “S” Science from all manner of quackery and nonsense. What Mastroianni rightly calls the “rise of peer review” took place between 1950 and 1970.
Turning this tide, Professor Jens Christian Schwamborn, a cellbiology expert at the University of Luxembourg and co-founder of OrganoTherapeutics , is leading a groundbreaking effort to transform our understanding and treatment of these debilitating diseases.
The funding will be used to develop a pipeline of ‘highly selective’ gene therapies targeting cancer stem cells in a variety of solid tumour types. It will draw on research led by Professor Steven Pollard at the University of Edinburgh, which delved into stem cellbiology, synthetic biology and cancer genomics.
In this blog post, KIF1A.ORG Chief Science Officer Dr. Dominique Lessard describes a unique cross disciplinary experience with multiple scientific stakeholders in the rare disease space, all focused around our holistic understanding of KAND. What do worms, a classroom full of students, and members of the KAND family community have in common?
Prior to joining the platform, Lipinski worked for almost five years as a postdoc with Paola Arlotta at Harvard Department of Stem Cell and Regenerative Biology and Stanley Center for Psychiatric Research. His work focused on basic biological mechanisms of cell identity and gene expression. Lipinski earned his Ph.D.
Can you tell us about your journey in the field of science, technology, engineering and maths (STEM) and the challenges you encountered along the way? At school I was encouraged to follow science because I was good at it. When it comes down to cellbiology itself, cells can do so many different things.
She has deep knowledge in Immunology and T cellbiology, and 13 years of experience in Research (seven of them in biotech at Immunocore), including pipeline programme leadership. Dr Ribeiro holds a PhD in Biomedical Sciences from University of Porto, Portugal, studying T cell and thymus development.
1 To address the urgent need for new therapies, the UK’s Medical Research Council (MRC), a national public agency supporting health science and research, established the Dementias Platform United Kingdom (DPUK) in 2014. Unless something is done, experts predict these numbers will likely double within the next 20 years.
24 scientists will receive both financial and scientific support for their crop science research proposal / Successful projects have the potential to become future collaborations with Bayer / Researchers selected from more than 600 proposals representing 39 countries.
As a female undergraduate student studying pharmaceutical sciences, one of the biggest challenges was not having enough female leaders as mentors. Science is our foundation at Allergan Aesthetics. Can you tell us about your journey in the field of STEM and the challenges you encountered along the way?
The custom-designed laboratory accommodates the growth in demand for advanced digital pathology and imaging capabilities, expertise in molecular sciences and a wide array of sequencing technologies. This convergence of trials, labs, and data sciences is driving faster clinical development and approval. Canada, Europe, and Australia.
The findings, which are described in the journals Nature Communications and Science Advances, could pave the way for new treatments against COVID-19. Science Advances, online March 25, 2022, doi: 10.1126/sciadv.abm0220. McInerney, Ben Murrell. Source link: [link].
million expansion will bring high quality seeds to worldwide markets faster, providing solutions for growers and meeting consumer demands / The seven-hectare global Product Design Center in San Nicolás includes state-of-the-art lab space for cellbiology research and greenhouses for seed production.
This discovery sheds new light on the intricate mechanisms at play within cancer cells when faced with adverse conditions. When bound to GRP78, ID2 loses its inhibitory function, leading to increased invasiveness of cancer cells.
Before joining Altasciences, Ria received a Bachelor of Science from McGill Universitys Department of Anatomy and CellBiology in 1998, and became a Diplomate of the American Board of Toxicology in October 2016.
Speaking at the virtual Capital Markets Day on Wednesday, CEO Werner Baumann emphasized Bayer’s long-term growth perspectives: “Bayer is a leading life science company, uniquely positioned at the intersection of health and nutrition – with attractive prospects for growth, earnings and cash flow.” through 2023.
A recently published study 1 from a large team of cell biologists sheds new light on cellular organisation and variability. This project started in the early days of the Allen Institute for CellScience, nearly seven years ago. Can you give a brief overview of your research methods?
Credit: National Center for Advancing Translational Sciences, NIH When you think of the causes of infectious diseases, what first comes to mind are probably viruses and bacteria. James Inglese, a researcher at NIH’s National Center for Advancing Translational Sciences, and his colleagues decided to take another look.
. “The problem is that cells only make small amounts of p53 and then quickly break it down as it is a very large and disordered protein,” says the study’s last author Michael Landreh, researcher at the Department of Microbiology, Tumor and CellBiology, Karolinska Institutet.
My role involved generating and characterizing complex proteins critical for biological assay development, hit discovery, and structural biology. During this time, I had the opportunity to step in as an interim Discovery Sciences project lead, sparking my interest in project leadership.
At school, I enjoyed sciences and anything practical—anything that was hands-on, where I could get stuck in. At university, I chose to combine my interests in biology and chemistry and take biochemistry. Science is very collaborative and you can’t achieve what you want to in isolation.
3 Part of the beauty of science is that it builds upon itself, one experiment at a time. Credit: Rob Phillips and Ron Milo, CellBiology by the Numbers. They are a starting point for experiments, allowing one to evaluate what is possible with biology versus what ought to remain consigned to the realms of science fiction.
in CellBiology from Utrecht University. UTRECHT, The Netherlands–( BUSINESS WIRE )– AM-Pharma B.V. , an emerging leader focused on the treatment of kidney disease, sepsis and organ injury, today announced the appointment of Maarten Kraan, M.D., as Chief Medical Officer and Teun van de Laar, Ph.D., About AM-Pharma.
A group of researchers at The Korean Advanced Institute of Science and Technology (KAIST) have found the underlying mechanism of plasticity, which could be related to neurological disorders in adult brains. Important connects are nurtured and reinforced while seemingly unnecessary ones are pruned.
About the author Dr Jia-Jia Zhang, Doctoral candidate Dr Jia-Jia Zhang is a doctoral candidate at the National Translational Science Center for Molecular Medicine & Department of CellBiology, Fourth Military Medical University, and her research interest is the development of therapeutical antibodies to treat human disease.
“Computer science is to biology what calculus is to physics.” Read Basic Science *mRNA decoding in human is kinetically and structurally distinct from bacteria. Read *T(STEM)-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models.
Basic Science *No evidence for a common blood microbiome based on a population study of 9,770 healthy humans. Read Health *Base editing rescue of spinal muscular atrophy in cells and in mice. Mice and human cells that were given the therapy had normal levels of the survival motor neuron protein, and no symptoms. Ricciardi M.J.
He brings extensive life sciences experience to the Company, gained primarily through his nearly 20-year career at Celgene where he built the medical infrastructure as the company evolved. At NexImmune, he will oversee all aspects of research and development.
Credit: Oriane Hidalgo Per the book CellBiology by the Numbers , each base pair of DNA occupies 1 nm 3 of space. The fern lives in a “relatively stable environment with little competition,” the authors of the recent study told Science. In other words, its large genome is neither helpful nor a hindrance.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content